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Background and purpose
Chronic pain and physical disability from juvenile idio-
pathic arthritis (JIA) limits patients' capacity to participate
in usual daily activities, and often cause children to miss
school and parents to miss work. The purpose of this
study was to investigate the change in activity participa-
tion in both children with JIA and their parents, following
abatacept treatment.
Methods
190 JIA patients were treated with abatacept for 4 months
in an open-label lead-in period (Period A). ACR Pedi 30
responders (n = 123) were then randomized 1:1 to receive
abatacept or placebo for 6 months in a double-blind with-
drawal period (Period B). Activity participation for the
child and the parents were assessed, along with clinical
and quality of life (QOL) parameters. Mean change from
baseline in each period was analyzed, and the two treat-
ment groups were compared.
Results
During Period A, there was a gradual reduction of missed
activity days for both children and parents. In Period B,
children randomized to continue abatacept reduced
another 1.5 days/month of missed school, compared to
an increase of 0.56 days/month from placebo. Parents of
abatacept patients maintained their gain in usual activity
from Period A, while parents of placebo patients had 1.1
days/month of missed activities. The improvements in
activity were consistent with clinical responses and QOL
improvements observed.
Conclusion
Abatacept treatment improved patient's ability to partici-
pate in daily activities and parents get back to usual daily
activities. This demonstrates real-life tangible benefits to
JIA patients as a result of clinical and QOL improvements.
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